Introduction
============

Acronyms---abbreviations formed from the initial components of a phrase or word[@ref1]---improve the perception of complex, written information.[@ref2] [@ref3] Within the health sciences, researchers' use of acronyms holds a long tradition, with the likely intention of branding their work into the minds of fellow researchers, clinicians, editors, or lay people.[@ref4]

The use of acronyms in health sciences has been subject to intense debate.[@ref5] Authors have advocated against such use as they claim it has turned into MMMMM---a major malady of modern medical miscommunication[@ref6]---and asserted that positive sounding acronyms are misused in clinical trials with negative outcomes.[@ref7] [@ref8] It has been suggested that editors should insist on eliminating the use of positive sounding acronyms[@ref9] or even bring a HALT (help acronyms leave (medical) trials) to the use of acronyms altogether.[@ref10]

This heated controversy seems to be based on opinion rather than founded on rigorous scientific research. Few quantitative studies of this important topic exist, and to our knowledge studies on the technical and aesthetic quality of acronyms are virtually absent. We describe the extent and quality of acronym use within different medical specialties.

Methods
=======

We included five major medical specialties in the analysis: cardiology, endocrinology, rheumatology, pulmonary medicine, and psychiatry. For each specialty we selected a disease that was central to the discipline and identified the most appropriate MeSH term for that disease. Using these MeSH terms, we searched PubMed for studies containing acronyms in their title that did not refer to a method (for example, randomised controlled trial). We restricted the search to randomised controlled trials in humans, reported in English, and published during 2000-12.

Acronym identification
----------------------

In the included studies we looked for the meaning of the acronym in several sources in the order of title, abstract, full text, and trial registration (if any). AP, MBH, and MRH performed the initial search, further aided by CG, TBS, KSL, PMM, LHVM, and DD in identifying acronyms. In case of any uncertainty by the single reviewer, the information was double checked by both MBH and MRH.

Acronym evaluation
------------------

The evaluation consisted of both positive (BEAUTY, Boosting Elegant Acronyms Using a Tally Yardstick) and negative (CHEATING, obsCure and awkHward usE of lettArs Trying to spell somethING) criteria (box). We used a two step Delphi method to agree on these criteria.[@ref11] The final score assigned to each acronym was obtained by adding the BEAUTY and CHEATING score.

### Criteria used for evaluation of acronyms

### Positive criteria

#### BEAUTY---Boosting Elegant Acronyms Using a Tally Yardstick

1.  Scores calculated:

    1.  1.5 points for each letter of acronym correctly used---that is, letters in the acronym that corresponded to the first letter in a word of the title

    2.  5 points if acronym was a real word

    3.  2 points if acronym related to the specialty of study

### Negative criteria

#### CHEATING---obsCure and awkHward usE of lettArs Trying to spell somethING

1.  Scores calculated:

    1.  −2 points for each letter incorrectly used---that is, not the first in a word

    2.  −1 point for each letter that was almost correctly used---that is, followed a correctly used letter

    3.  −1 point for each word in the full title not accounted for in the acronym (not counting prepositions and adverbs)

    4.  −2 points for each letter in the acronym that could not be attributed to a word in the full title

To assess the inter-rater reliability of the combined score we rescored 100 randomly selected acronyms.[@ref12] [@ref13] We also subjectively evaluated whether the acronym could be considered as "cool" (for example, had a witty cultural reference) or pretentious, or the quality of the language of the full title had suffered in a strained attempt to make the acronym fit better. We did not include these subjective measures in the overall score.

Finally, we identified a list of honourable and dishonourable mentions that for some reason did not obtain a particularly high or low score but still deserve to be highlighted.

Analysis
--------

We reported the proportion of acronym use and the median quality score of acronyms over time. We reported the 25 highest and lowest scoring acronyms and the honourable and dishonourable mentions selected by the reviewers. One way analysis of variance was used to compare overall scores between different medical specialties. To determine if the prevalence of acronyms in cardiology was higher than that in the other specialties, we performed a χ^2^ test. The change in quality of acronyms over time was assessed using a Spearman's rank correlation. For the top and bottom 25 acronyms, we identified the impact factor of the publishing journal in the year of publication, total number of citations, and average yearly citations.[@ref14] We compared the 25 highest and lowest scoring acronyms using an unpaired Student's *t* test after log transformation.

Results
=======

A total of 14 965 publications were identified, most of which were within the disciplines of cardiology (n=5063) and endocrinology (n=4994). Overall, 18.3% (n=2737) of the publications contained a total of 1149 unique acronyms (table 1[](#tbl1){ref-type="table"}). The prevalence proportion of acronyms increased over time for all specialties, except for cardiology (P\<0.01, fig 1[](#fig1){ref-type="fig"}).

###### 

 Basic search algorithm and results

  Specialty            MeSH term                                No of studies   No (%) with acronym in title   Total No of acronyms
  -------------------- ---------------------------------------- --------------- ------------------------------ ----------------------
  Cardiology           Myocardial infarction                    5063            1912 (37.8)                    804
  Endocrinology        Diabetes mellitus, type 2                4994            618 (12.4)                     299
  Rheumatology         Arthritis, rheumatoid                    1404            114 (8.1)                      69
  Pulmonary medicine   Pulmonary disease, chronic obstructive   1691            86 (5.1)                       50
  Psychiatry           Depressive disorder, major               2284            150 (6.6)                      49
  Total\*                                                       14 965          2737 (18.3)                    1149

\*Differs from sum as studies might be related to more than one keyword.

![**Fig 1** Prevalence proportion of acronyms over time](pota022787.f1_default){#fig1}

Excluding 197 acronyms where we could not identify the full meaning, 952 acronyms underwent further evaluation. The median quality score was 6.5, with scores ranging from −18 to 22 (interquartile range 3.0-10.5). One way analysis of variance showed that the correlation between score and medical specialty was not statistically significant. Tables 2[](#tbl2){ref-type="table"} and 3[](#tbl3){ref-type="table"} present the 25 highest and lowest scoring acronyms. Over the study period the acronym quality score declined significantly (P\<0.01, fig 2[](#fig2){ref-type="fig"}). The honourable and dishonourable mentions are listed in tables 4[](#tbl4){ref-type="table"} and 5[](#tbl5){ref-type="table"}.

###### 

 25 best acronyms according to composite BEAUTY and CHEATING criteria (see box for details of scoring)

  Total score   Acronym      Full name\*                                                                                                                             Specialty   Publication year   Impact factor   No of citations†   Citations /year†
  ------------- ------------ --------------------------------------------------------------------------------------------------------------------------------------- ----------- ------------------ --------------- ------------------ ------------------
  22.0          PREDICTIVE   Predictable Results and Experience in Diabetes through Intensification and Control to Target: An International Variability Evaluation   EN          2008               31.7            28                 4.7
  20.5          PERISCOPE    Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation                              EN          2008               31.7            375                53.6
  19.5          IMMEDIATE    Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency care                                    CA          2012               30.0            44                 14.7
  18.5          PRECISION    Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen                                           CA          2009               4.4             36                 6.0
  18.0          BARRICADE    Barrier approach to restenosis: restrict intima to curtail adverse events                                                               CA          2011               6.8             10                 2.5
  17.5          BRONCUS      Bronchitis Randomized on NAC Cost-Utility Study                                                                                         PU          2005               23.4            274                27.4
  17.5          CAPTIVATE    Carotid Atherosclerosis Progression Trial Investigating Vascular ACAT Inhibition Treatment Effects                                      CA          2009               28.9            60                 10.0
  17.5          PRISM-PLUS   Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms                         CA          2000               10.9            46                 3.1
  17.0          DECREASE     Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography                                                        CA          1999               28.9            816                51.0
  17.0          CHARISMA     Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance                                        CA          2004               3.7             126                11.5
  17.0          CADILLAC     Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications                                                   CA          2002               29.1            801                61.6
  17.0          INTERCEPT    Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis                                   CA          2000               10.2            49                 3.3
  17.0          MR-IMPACT    Magnetic Resonance Imaging for Myocardial Perfusion Assessment in Coronary Artery Disease Trial                                         CA          2008               8.9             216                30.9
  16.0          PLASMA       Phospholipase Levels and Serological Markers of Atherosclerosis                                                                         PU          2009               30.8            72                 12.0
  16.0          InTIME       Intravenous NPA for the treatment of infarcting myocardium early                                                                        CA          2000               3.8             108                7.2
  16.0          IMPACT       Improving Mood with Psychoanalytic and Cognitive Therapies                                                                              PS          2011               2.1             9                  2.3
  16.0          MICRO-HOPE   Microalbuminuria Cardiovascular Renal Outcomes - Heart Outcomes Prevention Evaluation                                                   CA          2000               10.2            \-                 \-
  16.0          BRIDGE       Blacks Receiving Interventions for Depression and Gaining Empowerment                                                                   PS          2013               2.5             2                  1.0
  16.0          APHRODITE    Active Prevention in High-Risk Individuals of Diabetes Type 2 in and Around Eindhoven                                                   EN          2011               8.1             13                 3.3
  16.0          CRUISE       Can Routine Ultrasound Influence Stent Expansion                                                                                        CA          2000               10.9            217                14.5
  15.5          SENIORS      Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure                          CA          2005               7.3             548                54.8
  15.5          CAPTORS      Collaborative Angiographic Patency Trial Of Recombinant Staphylokinase                                                                  CA          2000               2.4             19                 1.3
  15.5          DESMOND      Diabetes Education and Self Management for Ongoing and Newly Diagnosed type 2 Diabetes                                                  EN          2008               12.8            158                22.6
  15.5          ESSENCE      Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events                                                            CA          1997               27.8            1089               60.5
  15.5          COMPETE      Computerization of Medical Practices for the Enhancement of Therapeutic Effectiveness                                                   EN          2009               7.7             66                 11.0

CA=cardiology; EN=endocrinology; PU=pulmonary medicine; PS=psychiatry.

\*Capitalisation is identical to that done by authors of single study.

†Source: Web of Knowledge.^14^

###### 

 25 worst acronyms according to composite BEAUTY and CHEATING criteria (see box for details of scoring)

  Total score   Acronym            Full name\*                                                                                                                                                                                                 Specialty   Publication year   Impact factor   No of citations†   Citations/year†
  ------------- ------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------- ------------------ --------------- ------------------ -----------------
  −18.0         METGO              A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination METhotrexate and intramuscular GOld therapy in rheumatoid arthritis: results of the METGO study   RH          2005               7.4             57                 5.7
  −18.0         PERFORM            Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack                                    CA          2011               38.3            68                 17.0
  −16.5         TYPHOON            Trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty                                                                      CA          2011               6.8             50                 12.5
  −14.5         T-VENTURE          inhibitory effect of valsartan against progression of lefT VENTricUlaR dysfunction aftEr myocardial infarction                                                                                              CA          2009               2.7             11                 1.8
  −13.5         POLMIDES           Prospective randomised pilOt study evaLuating the safety and efficacy of hybrid revascularisation in MultI-vessel coronary artery DisEaSe                                                                   CA          2011               0.5             2                  0.5
  −13.0         BEAUTIFUL          morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction                                                                            CA          2008               28.4            355                50.7
  −12.0         CILON-T            Influence of CILostazol-based triple antiplatelet therapy ON Ischemic Complication after drug-eluting stenT implantation                                                                                    CA          2011               14.2            83                 20.8
  −12.0         AMEthyst           Assessment of the Medtronic AVE Interceptor Saphenous Vein Graft Filter System                                                                                                                              CA          2008               7.4             15                 2.1
  −11.0         EUCATAX            Efficacy and safety of a double-coated paclitaxel-eluting coronary stent                                                                                                                                    CA          2011               2.3             3                  0.8
  −11.0         RATIONAL           aspiRin stAtins or boTh for the reductIon of thrOmbin geNeration in diAbetic peopLe                                                                                                                         EN          2012               3.7             6                  2.0
  −10.5         ARMYDA-5 PRELOAD   Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty                                                                                                                                  CA          2010               14.3            26                 5.2
  −10.5         METOCARD-CNIC      Effect of METOprolol in CARDioproteCtioN during an acute myocardial InfarCtion                                                                                                                              CA          2012               4.5             7                  2.3
  −10.5         SIRTAX             SIRolimus-eluting stent compared with pacliTAXel-eluting stent for coronary revascularization                                                                                                               CA          2005               44.0            373                37.3
  −9.0          FABOLUS PRO        Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse                 CA          2012               6.6             33                 11.0
  −8.5          REGENT             Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction                                                                                       CA          2009               9.8             196                32.7
  −8.5          ORLICARDIA         ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes                                                                                                            EN          2004               2.9             29                 2.6
  −8.0          SCANDSTENT         Stenting Coronary Arteries in Non-Stress/Benestent Disease                                                                                                                                                  CA          2006               11.4            69                 7.7
  −8.0          RECOVER            REstoration of COronary flow in patients with no-reflow after primary coronary interVEntion of acute myocaRdial infarction                                                                                  CA          2012               4.5             4                  1.3
  −8.0          Carbostent         Carbofilm-coated stent versus a pure high-grade stainless steel stent                                                                                                                                       CA          2004               3.1             21                 1.9
  −7.0          VINO               Value of First Day Angiography/Angioplasty In Evolving Non-ST Segment Elevation Myocardial Infarction: An Open Multicenter Randomized Trial                                                                 CA          2002               6.1             95                 7.3
  −7.0          METIS              The effects of METhotrexate therapy on the physical capacity of patients with ISchemic heart failure                                                                                                        CA          2009               3.3             4                  0.7
  −7.0          STLLR              Stent deployment Techniques on cLinicaL outcomes of patients treated with the cypheRstent                                                                                                                   CA          2008               3.9             59                 8.4
  −6.5          COMFORTABLE        Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents                                                                                                                         CA          2012               3.3             6                  2.0
  −6.5          EXPIRA             Impact of Thrombectomy with EXPort Catheter in Infarct-Related Artery during Primary Percutaneous Coronary Intervention                                                                                     CA          2009               12.5            143                23.8
  −6.5          EXAMINE            EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome                                                        CA          2011               4.7             26                 6.5

CA=cardiology; EN=endocrinology; RH=rheumatology.

\*Capitalisation is identical to that done by authors of single study.

†Source: Web of Knowledge.^14^

###### 

 Honourable mentions

  Acronym       Full name\*                                                                                                                                                     Specialty
  ------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------
  CHAMPION      Cangrelor versus standard tHerapy to Achieve optimal Management of Platelet InhibitiON                                                                          CA
  ONTARGET      Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial                                                                               CA
  EXAMINATION   Clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION                                                                                        CA
  RATPAC        Randomised Assessment of Treatment using Panel Assay of Cardiac markers                                                                                         CA
  ALBATROSS     Aldosterone Lethal effects Blocked in Acute myocardial infarction Treated with or without Reperfusion to improve Outcome and Survival at Six months follow-up   CA
  ENIGMA        Evaluation of Nitrous oxide In the Gas Mixture for Anesthesia                                                                                                   CA
  PROTECT       Patient Related OuTcomes with Endeavor versus Cypher stenting Trial                                                                                             CA
  A to Z        Aggrastat to Zocor                                                                                                                                              CA
  DOCTORS       Debulking Of CTO with Rotational or directional atherectomy before Stenting                                                                                     CA
  DISPERSE      Dose confIrmation Study assessing anti-Platelet Effects of AZD6140 vs. clopidogRel in non-ST-segment Elevation myocardial infarction                            CA
  ADMIRAL       Abciximab Before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-term Follow-up                                               CA
  4D            Die Deutsche Diabetes Dialyse Studie                                                                                                                            CA
  VESPA         Verapamil Slow-Release for Prevention of Cardiovascular Events After Angioplasty                                                                                CA
  ALIVE         Azimilide Postinfarct Survival Evaluation                                                                                                                       CA
  LIFE          Losartan Intervention For Endpoint reduction in hypertension                                                                                                    CA
  OPERA         Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events                                                                                             CA
  HERO          Hirulog Early Reperfusion Occlusion                                                                                                                             CA
  MANTRA        Monitoring and Actualization of Noetic Training                                                                                                                 CA
  HI-5          Hyperglycemia: Intensive Insulin Infusion in Infarction                                                                                                         CA
  CHEER         Chest pain evaluation in the emergency room                                                                                                                     CA
  ILLUMINATE    Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events                                                                      EN
  SERENADE      Study Evaluating Rimonabant Efficacy in Drug-Naive Diabetic Patients                                                                                            EN
  CaRESS        Cardiovascular risk education and social support                                                                                                                EN
  DESSERT       Diabetes Drug Eluting Sirolimus Stent Experience in Restenosis Trial                                                                                            EN
  SLIM          Study on Lifestyle intervention and Impaired glucose tolerance Maastricht                                                                                       EN
  PLUTO         PLavix Use for Treatment Of Diabetes                                                                                                                            EN
  T-4           Treating to Twin Targets                                                                                                                                        RA

CA=cardiology; EN=endocrinology.

\*Capitalisation of letters is identical to that done by authors of single study.

###### 

 Dishonourable mentions

  Acronym      Full name\*                                                                                                                                                                                             Specialty
  ------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------
  SOLSTICE     LoSmapimod treatment on inflammation and InfarCtSizE                                                                                                                                                    CA
  MI FREEE     Post-Myocardial Infarction Free Rx Event and Economic Evaluation                                                                                                                                        CA
  SU.FOL.OM3   SUpplementation with FOLate, vitamins B-6 and B-12 and/or OMega-3 fatty acids                                                                                                                           CA
  PRODIGY      PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study                                                                                                            CA
  TAXUS        Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent                                                                                                                           CA
  ANTIBIO      Antibiotic Therapy in Acute Myocardial Infarction                                                                                                                                                       CA
  STRATEGY     Single High-Dose Bolus Tirofiban and Sirolimus Eluting Stent Versus Abciximab and Bare Metal Stent In Acute Myocardial Infarction                                                                       CA
  P-No SOS     Primary angioplasty in acute myocardial infarction at hospitals with no surgery on-site                                                                                                                 CA
  VICTORY      VeIn-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY                                                                                                                                    EN
  CAPPP        Captopril Prevention Project                                                                                                                                                                            EN
  MAXIMA       Maintenance of Haemoglobin Excels IV Administration of C.E.R.A.                                                                                                                                         PU
  ADJUST       Abatacept study to Determine the effectiveness in preventing the development of rheumatoid arthritis in patients with Undifferentiated inflammatory arthritis and to evaluate Safety and Tolerability   RA

CA=cardiology; EN=endocrinology; RH=rheumatology; PU=pulmonary medicine.

\*Capitalisation of letters is identical to that done by authors of single study.

![**Fig 2** Median quality score for acronyms by year](pota022787.f2_default){#fig2}

The intraclass correlation coefficient of the combined score was 0.91 (95% confidence interval 0.86 to 0.94), indicating almost perfect agreement.

Overall, 4.4% (n=42) of the acronyms contained poor language in an attempt to improve on the acronym, 11.5% (n=109) were designated as "cool," with cardiology and pulmonary medicine in the lead with 12.9% and 10.7%, respectively, and psychiatry, rheumatology, and endocrinology following with 2.8%, 5.8% and 9.8%, respectively. Although 12.8% (n=122) of all acronyms were classified as excessively pretentious, this proportion varied between specialties: from psychiatry (19.4%), rheumatology (15.4%), pulmonary medicine (14.3%), endocrinology (13.9%), to, lastly, cardiology (11.8%).

The top 25 acronyms were published in journals with a median impact factor of 10.2 (interquartile range 6.8-28.9), whereas the bottom 25 had a median impact factor of 6.1 (3.3-11.4). This difference failed to reach significance (P=0.05). The top 25 acronyms had more total citations (median 69 *v* 29, P=0.02), whereas citations per year did not differ significantly (median 14 *v* 7, P=0.09).

Discussion
==========

This quantitative and qualitative systematic study showed an increasing use of acronyms in the manuscript titles of four major medical specialties coinciding with a noticeable decline in the quality of the acronyms over time.

Cardiologists' obsession with acronyms is well documented and has been the subject of in-depth analysis.[@ref6] [@ref8] [@ref15] [@ref16] [@ref17] [@ref18] Although the "10 commandments of acronymology" was suggested in 2003,[@ref6] these were never formally adopted by any cardiological society. No biologically plausible reason explains the apparent obsession with acronyms in cardiology. It may be hypothesised that fierce academic competition spurred the origin of such use, and that new researchers have been subject to peer pressure and assigned acronyms at all cost to avoid academic marginalisation and ridicule. Another hypothesis is a reversal of the process: cardiologists may first concoct a clever acronym and then design a trial to fit that acronym.

Between the top 25 and bottom 25 acronyms, studies with good acronyms had more citations than studies with poor acronyms. For manuscript titles with good acronyms we observed a non-significant trend towards publication in journals with a higher impact factor. Bibliometric assessment of academic production is closely associated with successful funding,[@ref19] [@ref20] as well as personal satisfaction, pride, and peer prestige of researchers.[@ref21] [@ref22] [@ref23] In line with our findings, a study found that using an acronym was associated with a twofold increase in annual citation rate.[@ref24] Furthermore, the length of a manuscript's title has been identified as an independent predictor of citation rate.[@ref25] In that study, however, the authors failed to account for acronymisation in their regression model. This possibly represents a strong confounder, and we are confident that adjusting for acronym use would eliminate the apparent signal from title length.[@ref25] A causal relation cannot be inferred from our results though, and the issue of reverse causality remains a concern. We cannot exclude that well chosen and aesthetically satisfying acronyms increase the impact factor of the journals publishing them. However, we find it reassuring that acronyms that are technically correct and aesthetically satisfying are seemingly appropriately rewarded.

The Tolstoy manoeuvre
---------------------

We observed several examples of what we designate the Tolstoy manoeuvre: if the title appears to quote extensive passages from *War and Peace* (\>1400 pages), authors can fit any desired acronym by cherry picking letters. A striking example is ADJUST (Abatacept study to Determine the effectiveness in preventing the development of rheumatoid arthritis in patients with Undifferentiated inflammatory arthritis and to evaluate Safety and Tolerability, table 3). Incidentally, this represents a failed Tolstoy manoeuvre, as the "J" is not accounted for.

The good
--------

Good acronyms are thoughtful, well designed, orthographically correct, and aesthetically satisfying. Acronyms such as CHARISMA, PREDICTIVE, and CAPTIVATE (table 3) are excellent examples and all likely to serve the purpose of the acronymisation to a meaningful extent. For pure inventiveness and imagination, some very good acronyms were included on the honourable mentions list, such as HI-5, DESSERT, and RATPAC (table 4).

The bad
-------

The RATIONAL, RECOVER, and EXAMINE (table 3) acronyms may at first glance appear quite reasonable. On further examination, however, these acronyms reveal themselves to be poorly constructed. Consider the completely wonderful RATIONAL acronym, derived from "aspiRin stAtins or boTh for the reductIon of thrOmbin geNeration in diAbetic peopLe." Orthographically, a worse acronym than this is literally impossible to construct. Although the acronym signifies that the study presents rational, clinically important data, as in "rational pharmacotherapy" or "rational allocation of resources," such connotations seem disproportionate to the findings of the study.[@ref26]

The ugly
--------

We identified several acronyms that were seemingly randomly put together at the authors' discretion and did not remotely resemble a recognisable word or phrase. Prominent examples include POLMIDES, ARMYDA-5, and METGO (table 3). The dishonourable mentions list includes abominations such as SU.FOL.OM3 and P-No SOS (table 5), leaving acronymologists around the world wondering why the authors bothered in the first place.

We conclude that the prevalence of acronyms in reports on clinical trials is increasing at the expense of their semantic and aesthetic quality. Given the academic importance of acronyms, we are surprised by the lack of effort dedicated to their construction. The growth of acronym use, especially those of poor quality, should be resisted.[@ref27] We believe that strict governance of current guidelines by journal editors will result in an aesthetic improvement and better use of acronyms.

### What is already known on this topic

1.  The use of acronyms by medical researchers to brand their studies in the minds of clinicians and fellow researchers is subject to controversy

2.  The use of acronyms may be associated with a higher annual citation rate

### What this study adds

1.  The proportion of trials within major disease entities in rheumatology, endocrinology, pulmonary medicine, and psychiatry that uses acronyms is increasing

2.  The technical and aesthetic quality of acronyms is decreasing
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